Samuel Bates Martin is SVP AND CFO of Celldex Therapeutics, Inc.. Currently has a direct ownership of 28,125 shares of CLDX, which is worth approximately $742,500. The most recent transaction as insider was on Jun 14, 2024, when has been sold 17,172 shares (Common Stock) at a price of $35.42 per share, resulting in proceeds of $608,232. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 28.1K
0% 3M change
15.37% 12M change
Total Value Held $742,500

Samuel Bates Martin Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 14 2024
SELL
Open market or private sale
$608,232 $35.42 p/Share
17,172 Reduced 37.91%
28,125 Common Stock
Jun 14 2024
BUY
Exercise of conversion of derivative security
$195,639 $9.7 p/Share
20,169 Added 30.81%
45,297 Common Stock
May 30 2024
SELL
Open market or private sale
$1,191,750 $34.05 p/Share
35,000 Reduced 58.21%
25,128 Common Stock
May 30 2024
BUY
Exercise of conversion of derivative security
$259,500 $10.38 p/Share
25,000 Added 29.37%
60,128 Common Stock
Jan 02 2024
BUY
Exercise of conversion of derivative security
$29,884 $2.78 p/Share
10,750 Added 23.43%
35,128 Common Stock
Aug 12 2022
SELL
Open market or private sale
$624,498 $35.59 p/Share
17,547 Reduced 41.85%
24,378 Common Stock
Aug 12 2022
BUY
Exercise of conversion of derivative security
$103,527 $5.9 p/Share
17,547 Added 29.5%
41,925 Common Stock
Aug 11 2022
SELL
Open market or private sale
$90,859 $37.04 p/Share
2,453 Reduced 9.14%
24,378 Common Stock
Aug 11 2022
BUY
Exercise of conversion of derivative security
$22,126 $9.02 p/Share
2,453 Added 8.38%
26,831 Common Stock
Dec 23 2021
SELL
Open market or private sale
$399,000 $42.0 p/Share
9,500 Reduced 28.04%
24,378 Common Stock
Dec 23 2021
BUY
Exercise of conversion of derivative security
$41,300 $5.9 p/Share
7,000 Added 17.12%
33,878 Common Stock
Nov 15 2021
SELL
Open market or private sale
$409,355 $43.09 p/Share
9,500 Reduced 26.11%
26,878 Common Stock
Nov 15 2021
BUY
Exercise of conversion of derivative security
$41,300 $5.9 p/Share
7,000 Added 16.14%
36,378 Common Stock
Aug 10 2021
SELL
Open market or private sale
$123,894 $45.25 p/Share
2,738 Reduced 8.53%
29,378 Common Stock
Aug 10 2021
BUY
Exercise of conversion of derivative security
$126,148 $5.9 p/Share
21,381 Added 41.56%
30,060 Common Stock
SBM

Samuel Bates Martin

SVP AND CFO
Hampton, NJ

Track Institutional and Insider Activities on CLDX

Follow Celldex Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CLDX shares.

Notify only if

Insider Trading

Get notified when an Celldex Therapeutics, Inc. insider buys or sells CLDX shares.

Notify only if

News

Receive news related to Celldex Therapeutics, Inc.

Track Activities on CLDX